Bioaffinity Technologies, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on July 25, 2025. The Company, an emerging growth company incorporated in Delaware, reported that 28,459,541 shares of Common Stock were outstanding and entitled to vote as of the record date of May 29, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on seven proposals. All proposals were approved. Key outcomes include:
- Proposal 1 (Election of Directors): All seven nominees were elected. Notable vote counts included Maria Zannes (7,693,327 For) and Gary Rubin (7,426,487 For).
- Proposal 2 (Auditor Ratification): WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Proposal 3 (Reverse Stock Split): Approved an amendment to the Certificate of Incorporation to effect a Reverse Stock Split (11,606,440 For vs. 2,750,237 Against).
- Proposal 4 (Warrant Exercise Shares): Approved the issuance of up to 2,926,166 shares upon exercise of warrants issued in the February 26, 2025 private placement.
- Proposal 5 (Share Increase): Approved a Share Increase Amendment to the Certificate of Incorporation.
- Proposal 6 (Anti-Dilution Adjustment): Approved the anti-dilution provision for warrants issued in the May 7, 2025 public offering. This includes a reduction in exercise price (subject to a $0.10 floor) and a corresponding increase in issuable shares up to a maximum of 49,907,811 shares.
- Proposal 7 (Adjournment): Approved the ability to adjourn the meeting if necessary, though adjournment was not required as Proposals 3 through 6 were approved.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, or specific risk factors beyond the standard disclosure of voting results. The approval of the Reverse Stock Split and significant warrant adjustments (Proposals 3 and 6) indicate strategic actions to manage capital structure and share price.
Investor Verification Checklist
- Verify the specific ratio of the approved Reverse Stock Split (Proposal 3) in subsequent filings or press releases.
- Confirm the final exercise price and total share count resulting from the anti-dilution adjustment (Proposal 6) once calculations are finalized.
- Review the Definitive Proxy Statement filed on June 2, 2025, for detailed rationale behind the Share Increase Amendment (Proposal 5).
- Monitor the Company's compliance with Nasdaq listing standards following the Reverse Stock Split.